This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Nov 29;362(9398):1860.

doi: 10.1016/S0140-6736(03)14921-5.

What's major about adverse cardiac events?

Jonathan Silberberg

PMID: 14654342
DOI: 10.1016/S0140-6736(03)14921-5

Comment

What's major about adverse cardiac events?

Jonathan Silberberg. Lancet. 2003.

. 2003 Nov 29;362(9398):1860.

doi: 10.1016/S0140-6736(03)14921-5.

Author

Jonathan Silberberg

PMID: 14654342
DOI: 10.1016/S0140-6736(03)14921-5

No abstract available

PubMed Disclaimer

Comment on

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).
Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators. Schofer J, et al. Lancet. 2003 Oct 4;362(9390):1093-9. doi: 10.1016/S0140-6736(03)14462-5. Lancet. 2003. PMID: 14550694 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

What's major about adverse cardiac events?

What's major about adverse cardiac events?

Author

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources